Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Fund” third-quarter 2025 investor ...

Insulet Corporation (NASDAQ:PODD) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 9, Bernstein ...

PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for Insulet (NasdaqGS:PODD) from Equal-Weight to ...

Bernstein analyst Lee Hambright maintained a Buy rating on Insulet today and set a price target of $380.00. According to TipRanks, Hambright is a 4-star analyst with an average return of 8.1% and a 68 ...

Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...